4Maligie MA,Selitrennikoff CP.Cryptococcus neoformans resistance to echinocandins:(1,3)beta-glucan synthase activity is sensitive to echinocandins[J].Antimicrobial agents and chemotherapy,2005,49 (7):2851-2856 被引量：1
5Bartizal K,Gill CJ,Abruzzo GK,et al.In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)[J].Antimicrob Agents Chemother,1997,41 (11):2326-2332 被引量：1
6Graybill JR,Najvar LK,Montalbo EM,et al.Treatment of histoplasmosis with MK-991(-743,872)[J].Antimicrob Agents Chemother,1998,42 (1):151-153 被引量：1
7Hajdu R,Thompson R,Sundelof J G,et al.Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)[J].Antimicrob Agents Chemother,1997,41 (11):2339 -2344 被引量：1
7Falagas ME,Vardakas KZ,Michalopoulos A.In meta-analysis itraconazole is superior to fiuconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancies:response to Prentice et al.Br J Haematol.2006;132:658-659. 被引量：1
8S.B.Girois.F Chapuis.E.Decullier.B.G.P.Revol Adverse effects of antifhngal therapies in invasive fungal infections:review and meta-analysis Eur J Clin Microbiol InfEct.Dis(2006)25:138-149. 被引量：1
10Tawanda Gumbo,John Hiemenz,Lei Ma.Population pharmacokinetics of micafungin in adult patients.Diagnostic Microbiology and Infectious Disease.2008,60:329-331. 被引量：1
